Noctiva (desmopressin) - First in Class Product for Treatment of Nocturia

(Length of Presentation: 17 min)


Seymour Fein, Chief Medical Officer, principal and co-founder of Serenity Pharmaceuticals and head of the research team which developed Noctiva for the treatment of nocturia due to nocturnal polyuria presents the key clinical data which documents its efficacy, safety and clinical benefit as a treatment option for nocturia due to nocturnal polyuria in adults who awaken 2 or more times per night to void. 


Presenter Biography: Seymour Fein, MD, the Chief Medical Officer, principal and co-founder of Serenity Pharmaceuticals, board-certified in oncology and internal medicine.

Read More:
Efficacy and Safety of SER120 Nasal Spray in Nocturia Patients Pooled Analysis of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials.

Efficacy and Safety of SER120 Nasal Spray in Nocturia Patients Pooled Analysis of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials - Beyond the Abstract
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe